

Kevin G Blyth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8604333/publications.pdf>

Version: 2024-02-01

83
papers

2,221
citations

304368

22
h-index

243296

44
g-index

91
all docs

91
docs citations

91
times ranked

2808
citing authors

#	ARTICLE	IF	CITATIONS
1	Benign Pleural Thickening, Fibrosis and Plaques. , 2022, , 499-509.		0
2	Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> ,the, 2022, 10, 139-148.	5.2	18
3	Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*. <i>Critical Care Medicine</i> , 2022, 50, 398-409.	0.4	27
4	Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group. <i>Lung Cancer</i> , 2022, 164, 76-83.	0.9	1
5	Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria. <i>Thorax</i> , 2022, , thoraxjnl-2021-217808.	2.7	6
6	Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. <i>EBioMedicine</i> , 2022, 76, 103856.	2.7	38
7	Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). <i>EclinicalMedicine</i> , 2022, 47, 101409.	3.2	20
8	A multisystem, cardio-renal investigation of post-COVID-19 illness. <i>Nature Medicine</i> , 2022, 28, 1303-1313.	15.2	39
9	Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 886-890.	0.4	13
10	Estimating the False Positive Prediction Rate in Automated Volumetric Measurements of Malignant Pleural Mesothelioma. <i>Communications in Computer and Information Science</i> , 2021, , 116-139.	0.4	1
11	The Association Between Pleural Fluid Exposure and Survival in Pleural Mesothelioma. <i>Chest</i> , 2021, 160, 1925-1933.	0.4	8
12	Long-Term Outcomes after Severe COVID-19 Infection: A Multicenter Cohort Study of Family Member Outcomes. <i>Annals of the American Thoracic Society</i> , 2021, 18, 2098-2101.	1.5	2
13	Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement. <i>Lancet Respiratory Medicine</i> ,the, 2021, 9, 1050-1064.	5.2	26
14	Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1705-1717.	0.5	10
15	Intrapleural Fibrinolytics and Deoxyribonuclease for Treatment of Indwelling Pleural Catheter-Related Pleural Infection: A Multi-Center Observational Study. <i>Respiration</i> , 2021, 100, 452-460.	1.2	9
16	Long-term outcomes following severe COVID-19 infection: a propensity matched cohort study. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001080.	1.2	21
17	A randomised controlled trial of intrapleural balloon intercostal chest drains to prevent drain displacement. <i>European Respiratory Journal</i> , 2021, , 2101753.	3.1	1
18	Interobserver variation in image interpretation and the prognostic importance of nonexpansile lung in malignant pleural effusion. <i>Respirology</i> , 2020, 25, 298-304.	1.3	15

#	ARTICLE	IF	CITATIONS
19	Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions. JAMA - Journal of the American Medical Association, 2020, 323, 60.	3.8	79
20	Oncolytic herpesvirus therapy for mesothelioma – A phase I/IIa trial of intrapleural administration of HSV1716. Lung Cancer, 2020, 150, 145-151.	0.9	25
21	Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 935.	0.7	7
22	A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma. Lung Cancer, 2020, 150, 12-20.	0.9	11
23	COVID-19 associated with extensive pulmonary arterial, intracardiac and peripheral arterial thrombosis. BMJ Case Reports, 2020, 13, e237460.	0.2	14
24	The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study. Cardiovascular Research, 2020, 116, 2185-2196.	1.8	31
25	Chest drain aerosol generation in COVID-19 and emission reduction using a simple anti-viral filter. BMJ Open Respiratory Research, 2020, 7, e000710.	1.2	12
26	Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial. Lancet, The, 2020, 396, 39-49.	6.3	66
27	Mesothelioma: is chemotherapy alone a thing of the past?. , 2020, , 232-249.		1
28	Advanced Symptom Management System for Patients with Malignant Pleural Mesothelioma (ASyMSmeso): Mixed Methods Study. Journal of Medical Internet Research, 2020, 22, e19180.	2.1	12
29	Fully Automated Volumetric Measurement of Malignant Pleural Mesothelioma from Computed Tomography Images by Deep Learning: Preliminary Results of an Internal Validation. , 2020, , .		4
30	Mesothelioma is associated with ipsilateral thoracic muscle loss. , 2020, , .		1
31	Preliminary Results of the Meso-ORIGINS Feasibility Study. , 2020, , .		0
32	The association between pleural fluid exposure and survival in malignant pleural mesothelioma: a retrospective cohort study in 761 patients. , 2020, , .		0
33	Utility of pleural fluid for predictive marker testing in malignant pleural effusion. , 2020, , .		0
34	Pleural pointillism and early contrast enhancement as imaging biomarkers of pleural malignancy. , 2020, , .		0
35	Role of the pleural clinical nurse specialist in improving the patient pathway. , 2020, , .		0
36	Pre-EDIT. Chest, 2019, 156, 1204-1213.	0.4	22

#	ARTICLE	IF	CITATIONS
37	Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy – Data supporting –Direct to LAT™ in selected groups. Lung Cancer, 2019, 133, 123-129.	0.9	20
38	Continuous professional development: elevating thoracic oncology education in Europe. Breathe, 2019, 15, 279-285.	0.6	0
39	Cancer cachexia in thoracic malignancy: a narrative review. Current Opinion in Supportive and Palliative Care, 2019, 13, 316-322.	0.5	6
40	Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. Lung Cancer, 2019, 130, 108-114.	0.9	19
41	Lung cancer symptom appraisal among people with chronic obstructive pulmonary disease: A qualitative interview study. Psycho-Oncology, 2019, 28, 718-725.	1.0	16
42	Outcomes of intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) for IPC-related pleural infection. , 2019, , .		1
43	IPC-related pleural infection vs. colonisation - to treat or not to treat?. , 2019, , .		1
44	Potential bed-day savings in patients admitted unnecessarily for pleural investigation. , 2019, , .		0
45	Technical limitation of semi-automated volumetric analysis using CT in patients with Malignant Pleural Mesothelioma. , 2019, , .		1
46	Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors. BMJ Open Respiratory Research, 2018, 5, e000240.	1.2	132
47	Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy. Lung Cancer, 2018, 118, 48-56.	0.9	26
48	Estimating past inhalation exposure to asbestos: A tool for risk attribution and disease screening. International Journal of Hygiene and Environmental Health, 2018, 221, 27-32.	2.1	12
49	Empyema necessitans and a persistent air leak associated with rupture of an anaerobic lung abscess due to bacteroides. Thorax, 2018, 73, 91-93.	2.7	3
50	Progress and challenges in Mesothelioma: From bench to bedside. Respiratory Medicine, 2018, 134, 31-41.	1.3	25
51	A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels. Respiratory Medicine, 2018, 134, 117-123.	1.3	24
52	An Inconvenient Truth Concerning Surgery for Mesothelioma. Journal of Clinical Oncology, 2018, 36, 2745-2746.	0.8	2
53	Providing safe and effective pleural medicine services in the UK: an aspirational statement from UK pleural physicians. BMJ Open Respiratory Research, 2018, 5, e000307.	1.2	22
54	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 2018, 3, e000408.	2.0	4

#	ARTICLE	IF	CITATIONS
55	Predicting survival following surgical resection of lung cancer using clinical and pathological variables: The development and validation of the LNC-PATH score. <i>Lung Cancer</i> , 2018, 125, 29-34.	0.9	10
56	Results of pre-EDIT; a randomised feasibility trial of Elastance-Directed Intra-pleural catheter or Talc Pleurodesis (EDIT) in malignant pleural effusion. , 2018, , .		1
57	The DIAPHRAGM study: Diagnostic and prognostic biomarkers in the rational assessment of Mesothelioma. , 2018, , .		0
58	Pre-EDIT: protocol for a randomised feasibility trial of elastance-directed intrapleural catheter or talc pleurodesis (EDIT) in malignant pleural effusion. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000293.	1.2	5
59	The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. <i>Lung Cancer</i> , 2017, 103, 38-43.	0.9	40
60	Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'. <i>Cell Death and Differentiation</i> , 2017, 24, 1473-1474.	5.0	9
61	Dobutamine stress MRI in pulmonary hypertension: relationships between stress pulmonary artery relative area change, RV performance, and 10-year survival. <i>Pulmonary Circulation</i> , 2017, 7, 465-475.	0.8	4
62	Dose De-escalation of Intrapleural Tissue Plasminogen Activator Therapy for Pleural Infection. The Alteplase Dose Assessment for Pleural Infection Therapy Project. <i>Annals of the American Thoracic Society</i> , 2017, 14, 929-936.	1.5	74
63	Oncolytic herpesvirus therapy for mesothelioma: A phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018). <i>Annals of Oncology</i> , 2017, 28, v122.	0.6	15
64	Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. <i>European Respiratory Review</i> , 2016, 25, 472-486.	3.0	225
65	Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group. <i>Lung Cancer</i> , 2016, 101, 48-58.	0.9	38
66	Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study. <i>BMJ Open</i> , 2016, 6, e013324.	0.8	29
67	Mesobank UK: an international mesothelioma bioresource. <i>Thorax</i> , 2016, 71, 380-382.	2.7	26
68	Rescue therapy using an endobronchial valve and digital air leak monitoring in Invasive Pulmonary Aspergillosis. <i>Respiratory Medicine Case Reports</i> , 2015, 14, 27-29.	0.2	5
69	Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies. <i>Thorax</i> , 2015, 70, 374-374.	2.7	7
70	Blood-staining of pleural fluid is an inaccurate predictor of pleural malignancy. , 2015, , .		0
71	Intrapleural Tissue Plasminogen Activator and Deoxyribonuclease for Pleural Infection. An Effective and Safe Alternative to Surgery. <i>Annals of the American Thoracic Society</i> , 2014, 11, 1419-1425.	1.5	113
72	Changes in Right Ventricular Function Measured by Cardiac Magnetic Resonance Imaging in Patients Receiving Pulmonary Arterial Hypertension-Targeted Therapy. <i>Circulation: Cardiovascular Imaging</i> , 2014, 7, 107-114.	1.3	139

#	ARTICLE	IF	CITATIONS
73	Quantitative Estimation of Right Ventricular Hypertrophy using ECG Criteria in Patients with Pulmonary Hypertension: A Comparison with Cardiac MRI. <i>Pulmonary Circulation</i> , 2011, 1, 470-474.	0.8	16
74	The right operation for the wrong reason in multi-focal non-small cell lung cancer. <i>Respiratory Medicine CME</i> , 2010, 3, 40-43.	0.1	0
75	Assessment of the Presence of Occult Myocardial Infarction in Chronic Obstructive Pulmonary Disease Using Contrast-Enhanced Cardiac Magnetic Resonance Imaging. <i>Respiration</i> , 2009, 78, 263-269.	1.2	5
76	Vascular function assessed with cardiovascular magnetic resonance predicts survival in patients with advanced chronic kidney disease. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2008, 10, 39.	1.6	27
77	NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. <i>European Respiratory Journal</i> , 2007, 29, 737-744.	3.1	101
78	Pulmonary arterial pulse pressure and mortality in pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2007, 101, 2495-2501.	1.3	35
79	Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. <i>Kidney International</i> , 2006, 69, 1839-1845.	2.6	220
80	Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. <i>European Heart Journal</i> , 2005, 26, 1993-1999.	1.0	203
81	Measurement of Pulse Wave Velocity using Magnetic Resonance Imaging. , 2004, 2004, 3684-7.		8
82	There is insufficient evidence to support a screening programme for malignant pleural mesothelioma. <i>Shanghai Chest</i> , 0, 2, 42-42.	0.3	1
83	Advances in mesothelioma imaging and implications for surgical management. <i>Shanghai Chest</i> , 0, 2, 58-58.	0.3	1